Lenalidomide ( DrugBank: Lenalidomide )
8 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 16 | Crow-Fukase syndrome | 6 |
| 26 | HTLV-1-associated myelopathy | 2 |
| 28 | Systemic amyloidosis | 14 |
| 34 | Neurofibromatosis | 1 |
| 49 | Systemic lupus erythematosus | 1 |
| 284 | Diamond-Blackfan anemia | 1 |
| 300 | IgG4-related disease | 1 |
| 331 | Idiopathic multicentric castleman disease | 1 |
16. Crow-Fukase syndrome
Clinical trials : 13 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 4 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
26. HTLV-1-associated myelopathy
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
28. Systemic amyloidosis
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
284. Diamond-Blackfan anemia
Clinical trials : 36 / Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
300. IgG4-related disease
Clinical trials : 40 / Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
331. Idiopathic multicentric castleman disease
Clinical trials : 33 / Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|